# Aptevo Therapeutics to Present Multispecific Platform Data at SITC 2026 Meeting

- URL: https://stocks.freetheai.org/news/aptevo-therapeutics-to-present-multispecific-platform-data-at-sitc-2026-meeting-eb529e
- Published: 2026-10-14T12:46:00Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [NASDAQ:APVO](https://stocks.freetheai.org/symbols/NASDAQ-APVO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Aptevo Therapeutics Inc. (APVO) announced plans to present data on its multispecific antibody platform at the Society for Immunotherapy of Cancer 2026 Annual Meeting. The presentation will feature the clinical-stage biotechnology company's broader CD40-directed portfolio, which is designed to engage both innate and adaptive immune responses against solid tumors.

Solid tumors often suppress immune activity, making it harder for the body to fight cancer. Aptevo Therapeutics Inc. (APVO) uses its proprietary ADAPTIR and ADAPTIR-FLEX technologies to design therapies that activate CD40 and T cells directly inside the tumor microenvironment. This localized approach aims to generate a stronger anti-tumor immune response while minimizing systemic immune activation throughout the rest of the body.

The SITC 2026 meeting will take place from November 4 to November 8, 2026, in Phoenix, Arizona. A copy of presentation abstract 1060 will be made available on the publications page of the company's website following the conference. Shares of the company traded down 5.79% to $1.73 on the day of the announcement.

## Key points

- Aptevo Therapeutics Inc. (APVO) will present its CD40-directed multispecific technology platform at the SITC 2026 Annual Meeting.
- The presentation will take place November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona under abstract number 1060.
- The company's multispecific platform targets both innate and adaptive immunity within the tumor microenvironment to treat solid tumors.
- Shares of Aptevo Therapeutics fell 5.79% to $1.73 on the day of the announcement.

## Questions and answers

### When and where will Aptevo Therapeutics present at SITC 2026?

Aptevo Therapeutics will present at the Society for Immunotherapy of Cancer 2026 Annual Meeting, held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.

### What is the focus of Aptevo Therapeutics' presentation?

The presentation focuses on Aptevo's CD40-directed multispecific platform, which coordinates innate and adaptive immune responses directly within the tumor microenvironment to combat solid tumors.

### How did APVO stock react to the news?

Shares of Aptevo Therapeutics (NASDAQ:APVO) declined 5.79% to $1.73 on the day of the announcement.